J Cancer 2019; 10(21):5212-5222. doi:10.7150/jca.31697 This issue Cite
1. Department of Radiation Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China
2. Department of Radiation Oncology, The Fourth Affiliated Hospital of Anhui Medical University, Hefei, China
3. Department of Gynecology, Maternity and Child Healthcare Hospital of Anhui Medical University, Hefei, China
4. Department of Oncology, Fuyang Hospital of Anhui Medical University, Fuyang, Anhui, China
5. Department of Pathology, Maternity and Child Healthcare Hospital of Anhui Medical University, Hefei, China
6. Pathology Department of Anhui Medical University, Hefei, China
7. The Comprehensive Lab, College of Basic medicine, Anhui Medical University, Hefei, China
8. State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, China
# These authors have contributed equally to this work.
Amplified in breast cancer 1 (AIB1) gene, has been reported to be associated with biological malignancy in several cancers. However, the molecular status of the AIB1 gene in cervical cancer and the clinicopathological/prognostic significance of AIB1 expression in chemoradiotherapy (CRT) sensitivity have not been determined. In our present study, we found that the high expression of AIB1 was frequent detected in specimens of cervical cancer patients, and this was significantly correlated with CRT response (P = 0.014), clinical stage (P = 0.003), T status (P = 0.027), N status (P = 0.021), M status (P = 0.015) and progression-free survival (P < 0.001). Moreover, the clonogenic survival fraction and cell apoptosis experiments showed that knockdown of AIB1 substantially increased cervical cancer cells sensitivity to ionizing radiation (IR) or cisplatin/5-fluorouracil. Collectively, our results demonstrated that the high expression of AIB1 in cervical cancer cells contributes to the resistance to CRT, which provides the evidence that AIB1 may be a promising predictor of aggressive cervical cancer patients with poor response to CRT.
Keywords: Cervical cancer, AIB1, immunohistochemistry, chemoradiotherapy, Linear-Quadratic Model